Ex vivo study of bevacizumab transport through porcine nasal mucosa

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 80, Issue 2, 2012, Pages 465-469

  Samson, Géraldine ^a,b,c   García De La Calera, Alicia ^d,e   Dupuis Girod, Sophie ^b,c,f   Faure, Frédéric ^d   Decullier, Evelyne ^a,b,c   Paintaud, Gilles ^g,h,i   Vignault, Céline ^g,h,i   Scoazec, Jean Yves ^d,j   Pivot, Christine ^d   Plauchu, Henri ^c,f   Pirot, Fabrice ^d,e  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Clinical and Therapeutic Aspects of the Skin Barrier Function   (France)

^f LOUIS PRADEL HOSPITAL   (France)

^g CHU BRETONNEAU   (France)

^h CNRS   (France)

ⁱ UNIVERSITÉ DE TOURS   (France)

^j ANIPATH Centre d'Histopathologie du Petit Animal de Laboratoire   (France)

more..

Author keywords

Bevacizumab; Hereditary hemorrhagic telangectasia; Monoclonal antibody; Pharmacokinetics; Transmucosal transport

Indexed keywords

BEVACIZUMAB;

ANIMAL TISSUE; CLINICAL TRIAL (TOPIC); CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HISTOLOGY; MOLECULAR WEIGHT; NONHUMAN; NOSE MUCOSA; RENDU OSLER WEBER DISEASE;

ADMINISTRATION, INTRANASAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DIFFUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; NASAL MUCOSA; PERMEABILITY; SWINE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84856595002     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.11.004     Document Type: Conference Paper

References (10)

1. A. Mitchell, L.A. Adams, G. MacQuillan, J. Tibballs, R. vanden Driesen, and L. Delriviere Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia Liver Transpl. 14 2008 210 213 (Pubitemid 351267278)
2. T.T. Karnezis, and T.M. Davidson Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis Laryngoscope 121 2011 636 638
3. C. Wadell, E. Bjork, and O. Camber Nasal drug delivery-evaluation of an in vitro model using porcine nasal mucosa Eur. J. Pharm. Sci. 7 1999 197 206 (Pubitemid 29015736)
4. C. Wadell, E. Bjork, and O. Camber Permeability of porcine nasal mucosa correlated with human nasal absorption Eur. J. Pharm. Sci. 18 2003 47 53 (Pubitemid 36120554)
5. H.R. Costantino, L. Illum, G. Brandt, P.H. Johnson, and S.C. Quay Intranasal delivery: physicochemical and therapeutic aspects Int. J. Pharm. 337 2007 1 24 (Pubitemid 46756063)
6. D. Ternant, N. Ceze, T. Lecomte, D. Degenne, A.C. Duveau, H. Watier, E. Dorval, and G. Paintaud An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics Ther. Drug Monit. 32 2010 647 652
7. F. Pirot, Y.N. Kalia, A.L. Stinchcomb, G. Keating, A. Bunge, and R.H. Guy Characterization of the permeability barrier of human skin in vivo Proc. Natl. Acad. Sci. USA 94 1997 1562 1567 (Pubitemid 27087891)
8. S. Turker, E. Onur, and Y. Ozer Nasal route and drug delivery systems Pharm. World Sci. 26 2004 137 142 (Pubitemid 39012580)
9. A.J. Bitonti, and J.A. Dumont Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway Adv. Drug Deliv. Rev. 58 2006 1106 1118 (Pubitemid 44709269)
10. K. Cui, B.H. Dutzar, Method for Opening Tight Junctions, United States Patent US 2007/0253956 A1, 2007.